Clive Dix updates Proactive London's Andrew Scott on progress across the firm's portfolio.
He says they're very confident of delivering deals in the near future.
27 September 2019 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, is pleased to note Indivior PLC’s announcement that the National Institutes of Health (NIH) has granted Indivior's application entitled "Clinical Evaluation of C4X3256, a Non-Opioid, Highly-Selective Orexin-1 Receptor Antagonist for the Treatment of Opioid Use Disorder" pursuant to Funding Opportunity Announcement RFA-DA-19-002 dedicated to the development of medications to prevent and treat opioid use disorder and overdose.
2 September 2019 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, today announces that Robin Carr, a renowned industry veteran who has worked at GSK and Astex, is to head up and form a C4XD Drug Discovery Advisory Network.
At least one biotechnology company that develops new drugs for a living has created its own virtual reality platform for drug discovery. Founded in 2007, C4X Discovery (C4XD) out of Manchester, England, is a small-cap public company that has developed its own VR platform called 4Sight.
Dr Craig Fox, Chief Scientific Officer of C4X Discovery #C4XD discusses their collaboration with PhoreMost to accelerate Parkinson's Disease drug discovery pipeline.
(Interview starts at 10 minutes 15 seconds)
Chemists at C4X Discovery are using the virtual reality technology behind popular game Fortnite to visualize the structure of complex molecules. The tool, called 4Sight, has already been used to create a drug that is now in development to treat addiction.
25 June 2019 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, today entered into a collaboration with PhoreMost, a UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets. The collaboration, focused initially in Parkinson’s Disease, will combine both company’s technology platforms.